Cite

HARVARD Citation

    Desai, A. et al. (2022). Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro-oncology. 24 (10), pp. 1776-1789. [Online]. 
  
Back to record